(Q50852837)

24 March 2018

title

The antitumor effect of metformin with and without carboplatin on primary endometrioid endometrial carcinoma in vivo. (English)

1 reference

24 March 2018

1 reference

endometrial carcinoma

1 reference

1 reference

5

Diether Lambrechts

1 reference

24 March 2018

6

Frédéric Amant

1 reference

24 March 2018

author name string

Stefanie Schrauwen

1

1 reference

24 March 2018

Lieve Coenegrachts

2

1 reference

24 March 2018

Anna Cattaneo

3

1 reference

24 March 2018

Els Hermans

4

1 reference

24 March 2018

language of work or name

English

0 references

publication date

4 June 2015

1 reference

24 March 2018

published in

Gynecologic Oncology

1 reference

24 March 2018

volume

138

1 reference

24 March 2018

issue

2

1 reference

24 March 2018

page(s)

378-382

1 reference

24 March 2018

cites work

Cancer statistics, 2014

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Advances in the management of recurrent endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Cellular and molecular mechanisms of metformin: an overview

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

AMP-activated protein kinase: a target for drugs both ancient and modern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Integrated genomic characterization of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin: from mechanisms of action to therapies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin is associated with improved survival in endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin--mode of action and clinical implications for diabetes and cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Evaluating cell lines as tumour models by comparison of genomic profiles

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Establishment, characterization and comparison of seven authentic anaplastic thyroid cancer cell lines retaining clinical features of the original tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Microsatellite instable and microsatellite stable primary endometrial carcinoma cells and their subcutaneous and orthotopic xenografts recapitulate the characteristics of the corresponding primary tumor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin therapy and clinical uses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Dose translation from animal to human studies revisited

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin potentiates the effects of paclitaxel in endometrial cancer cells through inhibition of cell proliferation and modulation of the mTOR pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

K‑ras gene mutation as a predictor of cancer cell responsiveness to metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Another surprise from Metformin: novel mechanism of action via K-Ras influences endometrial cancer response to therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin, at concentrations corresponding to the treatment of diabetes, potentiates the cytotoxic effects of carboplatin in cultures of ovarian cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Metformin promotes progesterone receptor expression via inhibition of mammalian target of rapamycin (mTOR) in endometrial cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Immune-mediated antitumor effect by type 2 diabetes drug, metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

Role of organic cation transporter 3 (SLC22A3) and its missense variants in the pharmacologic action of metformin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2015.06.006

10.1016/J.YGYNO.2015.06.006

7 January 2021

Identifiers

DOI

1 reference

24 March 2018

PubMed ID

26050920

1 reference

24 March 2018